Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Current Leases (2020 - 2025)

Crescent Biopharma (CBIO) has disclosed Current Leases for 6 consecutive years, with $400000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases changed N/A to $400000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $400000.0, a N/A change, with the full-year FY2025 number at $400000.0, changed N/A from a year prior.
  • Current Leases was $400000.0 for Q4 2025 at Crescent Biopharma, down from $417000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.1 million in Q3 2022 to a low of $200000.0 in Q2 2025.
  • A 5-year average of $736560.4 and a median of $784930.5 in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: tumbled 65.03% in 2024, then surged 59.08% in 2025.
  • Crescent Biopharma's Current Leases stood at $1.0 million in 2021, then dropped by 8.27% to $918555.0 in 2022, then dropped by 19.27% to $741558.0 in 2023, then plummeted by 64.65% to $262133.0 in 2024, then soared by 52.59% to $400000.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Current Leases are $400000.0 (Q4 2025), $417000.0 (Q3 2025), and $200000.0 (Q2 2025).